Lipocine Inc. Files Q1 2025 10-Q Report
Ticker: LPCN · Form: 10-Q · Filed: 2025-05-08T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceutical
TL;DR
Lipocine Inc. Q1 2025 10-Q filed. Check financials.
AI Summary
Lipocine Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business operations. Specific financial figures and operational details are available within the full filing.
Why It Matters
This filing provides investors with the latest financial performance and operational status of Lipocine Inc., crucial for understanding the company's trajectory and investment potential.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Lipocine Inc. faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Period End Date (The end of the fiscal quarter reported)
- 2025-05-08 — Filing Date (The date the report was submitted to the SEC)
Key Players & Entities
- Lipocine Inc. (company) — Filer of the 10-Q report
- 0001641172-25-009180 (accession_number) — Unique identifier for the filing
- 20250331 (date) — End of the reporting period
- 20250508 (date) — Filing date
- SALT LAKE CITY (location) — City where Lipocine Inc. is located
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 8, 2025.
What is the company's name and Central Index Key (CIK)?
The company's name is Lipocine Inc., and its CIK is 0001535955.
Where is Lipocine Inc. located?
Lipocine Inc. is located at 675 Arapeen Drive, Suite 202, Salt Lake City, UT 84108.
What is the Standard Industrial Classification (SIC) code for Lipocine Inc.?
The SIC code for Lipocine Inc. is 2834, which corresponds to Pharmaceutical Preparations.
From the Filing
0001641172-25-009180.txt : 20250508 0001641172-25-009180.hdr.sgml : 20250508 20250508093020 ACCESSION NUMBER: 0001641172-25-009180 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250508 DATE AS OF CHANGE: 20250508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 25924216 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 10-Q 1 form10-q.htm 10-Q false --12-31 Q1 0001535955 0001535955 2025-01-01 2025-03-31 0001535955 2025-05-07 0001535955 2025-03-31 0001535955 2024-12-31 0001535955 2024-01-01 2024-03-31 0001535955 us-gaap:CommonStockMember 2023-12-31 0001535955 us-gaap:TreasuryStockCommonMember 2023-12-31 0001535955 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001535955 us-gaap:RetainedEarningsMember 2023-12-31 0001535955 2023-12-31 0001535955 us-gaap:CommonStockMember 2024-12-31 0001535955 us-gaap:TreasuryStockCommonMember 2024-12-31 0001535955 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001535955 us-gaap:RetainedEarningsMember 2024-12-31 0001535955 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001535955 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001535955 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001535955 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001535955 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001535955 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001535955 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001535955 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001535955 us-gaap:CommonStockMember 2024-03-31 0001535955 us-gaap:TreasuryStockCommonMember 2024-03-31 0001535955 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001535955 us-gaap:RetainedEarningsMember 2024-03-31 0001535955 2024-03-31 0001535955 us-gaap:CommonStockMember 2025-03-31 0001535955 us-gaap:TreasuryStockCommonMember 2025-03-31 0001535955 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001535955 us-gaap:RetainedEarningsMember 2025-03-31 0001535955 LPCN:LicenseAgreementMember LPCN:GordonSilverLimitedMember 2024-01-12 2024-01-12 0001535955 LPCN:LicenseAgreementMember LPCN:GordonSilverLimitedMember 2024-02-01 2024-02-01 0001535955 LPCN:LicenseAgreementMember LPCN:GordonSilverLimitedMember 2024-12-30 2024-12-30 0001535955 LPCN:LicenseAgreementMember LPCN:GordonSilverLimitedMember srt:ScenarioForecastMember 2026-01-01 2026-01-01 0001535955 LPCN:LicenseAgreementMember LPCN:GordonSilverLimitedMember srt:MinimumMember 2024-01-12 2024-01-12 0001535955 LPCN:LicenseAgreementMember LPCN:GordonSilverLimitedMember srt:MaximumMember 2024-01-12 2024-01-12 0001535955 LPCN:MajorCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001535955 LPCN:VerityLicenseAgreementMember 2025-01-01 2025-03-31 0001535955 LPCN:VerityLicenseAgreementMember us-gaap:LicenseMember 2024-01-01 2024-03-31 0001535955 LPCN:VerityLicenseAgreementMember 2024-01-01 2024-03-31 0001535955 u